In conclusion, the present study begins to unravel the BCR and TCR repertoire in WAS patients and paves the road for a better understanding of the differences in response to treatment such as bone marrow transplantation and gene therapy, the latter currently in clinical trial (5, 7, 24). The gene discussed is BCR; the disease is Wiskott-Aldrich syndrome.